What is The COVID-19 Global Rheumatology Alliance?

We are an international rheumatology community of physicians, patients, researchers, and other healthcare providers that quickly recognized the need to understand the impact of COVID-19 on the global rheumatology community. Our projects collect data from providers and patients on COVID-19-specific outcomes in patients with rheumatic diseases.

How does a healthcare provider report a case?

Healthcare providers are encouraged to report all cases of COVID-19 in patients with rheumatic diseases, regardless of severity, using our registry survey available at rheum-covid.org by clicking on the Provider-Entered Registries link.

How can patients participate?

Patients with a rheumatic disease who are at least 18 years old, as well as parents of children under 18 years old with a rheumatic disease, can complete a survey at rheum-covid.org by clicking on the Patient-Experience Survey link. Any patient from any country in the world can participate, whether or not they have had COVID-19.

Does this have IRB/Ethics approval?

Our Provider-Entered Registry has IRB approval from UCSF and was determined to not constitute human subjects research as defined under federal regulations 45 CFR 46.102. EULAR reviewed the protocol using the UK Health Research Authority decision tool and determined that the registry is not classified as a research study, UK National Health Service (NHS) ethics approval is NOT required, and patient consent is not required. The Patient-Experience Survey has IRB approval at Boston Children’s Hospital and was determined to be exempt because it is limited to research activities in which there is only limited involvement of human subjects described in 45 CFR 46.104 (d).